Treatment of Bone Metastases in Multiple Myeloma with Myeloma Bone Disease (Creatinine Clearance ≥60 ml/min)
Clinical Scenario
This protocol applies to patients with multiple myeloma who have developed myeloma bone disease — a direct skeletal complication of myeloma — and whose renal function is adequate, defined as a creatinine clearance of at least 60 ml/min.
Multiple myeloma · Myeloma bone disease · CrCl ≥60 ml/min
Role of Renal Function in Agent Selection
Renal function directly determines which bone-targeted options are appropriate. At creatinine clearance ≥60 ml/min, the full range of bone-targeted agents is clinically available.
When creatinine clearance falls below 60 ml/min, agent selection shifts — that is a separate protocol. This page addresses patients who meet the ≥60 ml/min threshold.
Treatment Approach (Partial Overview)
Bone-targeted therapy should be initiated at the time of multiple myeloma diagnosis. The approach involves parenteral agents from the bisphosphonate class as well as a non-bisphosphonate alternative.
Therapy is not necessarily indefinite — for patients who achieve remission, a structured de-escalation or interruption strategy may be appropriate. The specific criteria and timing are defined in the full protocol.
References
DOI: 10.1016/j.annonc.2020.07.019
- Zoledronate, pamidronate or denosumab should be initiated at diagnosis of MM.
- Denosumab is the agent of choice in MM patients with renal impairment (creatinine clearance <60 ml/min).
- Therapy with a bisphosphonate can be interrupted after 2 years in patients in remission.
- Most patients selected for treatment with zoledronate can de-escalate this agent safely to administration every 12 weeks, preferably after monthly treatment for 3-6 months.
View source ↗